Cancer and Leukemia Group B - The Ohio State University

癌症和白血病 B 组 - 俄亥俄州立大学

• 批准号: 7048482
• 负责人: CLARA D BLOOMFIELD
• 金额: $ 37.49万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-16 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7048482
• 关键词: AIDS related neoplasm /cancer; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; clinical research; clinical trial phase I; clinical trial phase II; clinical trial phase III; combination cancer therapy; combination chemotherapy; cooperative study; drug screening /evaluation; early diagnosis; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; prostate neoplasms; psychological aspect of cancer; quality of life; respiratory neoplasm

DESCRIPTION (provided by applicant): The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multidisciplinary collaborative research approach at OSU has a tract record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast cancer, gastrointestinal cancers, genitourinary malignancies, hematologic malignancies, lung cancer and melanoma. This research focuses the efforts of medical and hematologic oncologists, surgeons, radiotherapists, transplanters, psychiatrists, pathologists, cytogeneticists, translational laboratory scientists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk. Included in this project are: 1) the exploration of new therapeutic agents, and their associated toxicities, in Phase I, II and III clinical trials; 2) the evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology and biostatistics in the formulation and execution of specific therapy protocols; 5) the improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) the evaluation of biologic studies in correlation with clinical endpoint to develop more rationally based cancer management, 7) the evaluation of cancer controls efforts such as early detection, and 8) the study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core laboratories and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors.

描述（由申请人提供）：这笔赠款的目的是通过为俄亥俄州立大学 (OSU) 的 CALGB 项目提供必要的基础设施来支持癌症和白血病 B 组 (CALGB) 的科学和临床活动。俄勒冈州立大学的多学科合作研究方法在提供更有效的成人癌症预防、检测和治疗方法方面有着丰富的经验，特别关注乳腺癌、胃肠道癌症、泌尿生殖系统恶性肿瘤、血液系统恶性肿瘤、肺癌和黑色素瘤。这项研究集中了医学和血液肿瘤学家、外科医生、放射治疗师、移植师、精神科医生、病理学家、细胞遗传学家、转化实验室科学家、基础科学家、统计学家、流行病学家、护士、药剂师和临床研究人员的努力，精心设计和实施研究，提出相互关联的临床和基础科学问题，这些问题的答案对患者护理和减少人群中的癌症做出了重大贡献 风险增加。该项目包括：1）在I、II和III期临床试验中探索新的治疗药物及其相关毒性； 2）评估新疗法的疗效和毒性，包括新旧药物的组合，以更有效地开发协同组合； 3) 采用最佳组合的手术、免疫和放射治疗措施，开发针对特定肿瘤问题的多模式方法； 4）分子遗传学、生物化学、药理学、免疫学和生物统计学等相关基础科学学科参与具体治疗方案的制定和执行； 5) 通过使用这些方案来教育博士前和博士后学生、护士、专职医务人员和医生，改善社区的癌症护理，6) 评估与临床终点相关的生物学研究，以制定更合理的癌症管理，7) 评估癌症控制工作，如早期检测，以及 8) 研究癌症的心理社会方面。在医学博士 Clara D. Bloomfield 的总体协调下，OSU 通过患者应计方案、研究方案的制定和领导、领导和参与 CALGB 的科学和管理委员会、容纳多个 CALGB 核心实验室和设施、参与 CALGB 会议和撰写集团出版物，为 CALGB 活动做出贡献。此外，俄勒冈州立大学还进行机构试点并提供实验室数据，以开展新的 CALGB 研究。该计划的支持应能提高我们预防、检测、治疗和治愈成人癌症的能力，并提高癌症幸存者的生活质量。